Most Popular Stories
- Healthcare jobs will grow the fastest of all industries
- Hospitals lose reimbursement for 'unnecessary' ER visits
- Online tools, social media ease clinical recruiting, research
- Measuring ROI key to EHR success, adoption
- eHealth Initiative issues IT recommendations for ACOs
- Patient satisfaction equal for physician, hospitalist care
Featured Jobs
-
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA -
Epic Ambulatory Beacon Consultant
Meditology Services - NC
Events
- IHI's Transforming the Primary Care Practice
May 1-3, 2012 — San Diego, CA - CIO Healthcare Summit
March 11-14 — Scottsdale, AZ - Medical Devices Summit 2012
March 6-7 2012 — The Boston Park Plaza Hotel & Towers, Boston, MA - IHI's Breakthrough Series College
April 11-13, 2012 — Cambridge, MA
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
SPOTLIGHT: FDA drug safety official appointed
October 19, 2005 — 7:01pm ET
Tools
After a two year search, a new head of the FDA's Office of Drug Safety has been named. Dr. Gerald Dal Pan, an official with the Center of Drug Evaluation and Research who has been with the agency for five years, was appointed to the post Wednesday. The Office of Drug Safety is among the most closely watched units in the agency given recent concerns about FDA oversight of new drugs. Article
SHARE WITH:
Related Stories
- GAO report details problems at FDA
- Study: 'No link' between approval time, drug safety
- September hearings seen as test for FDA
- Merck seen as 'behind' in first Vioxx trial
- Pharma: U.S. health reform could hinder new drug development
- SPOTLIGHT: Pharma influence goes beyond gifts
- Study: Journal articles about drug trials missing or incorrect
- Studies raise questions about how much drug safety info should be released
- FDA may get $275 million more for staff, outsourcing
- Merck agrees to $58M settlement on Vioxx ads
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
